Hot Investor Mandate 2: Texas VC Seeks IT-Enabled Healthcare Devices and Services

A venture capital firm based in Texas and committed to enabling healthcare innovation is currently investing out of its latest fund of $200 million. The firm typically makes initial, equity investments of $10M, with the possibility to allocate up to $35M over the life of the investment.

The firm is currently most interested in the medtech and healthcare IT space, specifically IT-enabled healthcare devices and services. The firm is not interested in traditional medical devices without a software/data-driven component. The firm is indication agnostic, but has particular interest in neurology, cardiology, pulmonology, hearing, and wound care.

The firm seeks to invest in revenue-generating companies with a minimum of $2M-$3M in revenues, although there are no EBIDTA requirements and it is not required that the company be cash-flow positive. The firm will also look at pre-revenue companies on a secondary basis, with the caveat being that there is a clear line of sight to revenue generation. The firm only invests in U.S.-based companies with clinical data.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Cross-Border Fund Seeks Biotech, Medtech & Diagnostics in USA and China

A venture capital firm founded in 2006 with offices across China and in the US has invested in nearly 50 healthcare companies across all sectors of life sciences from pharmaceuticals and medical devices to healthcare IT and diagnostics. The firm typically leads investments, though is also open to co-investing. The firm typically makes equity investments ranging from $1-$35 million, and currently has $1.7 billion in total assets under management, with their latest fund raised in Feb. 2016 at $648 million. The firm seeks to make 20-30 new investments within the next year, with a geographical focus in China. The firm is open to opportunities in the US, as the firm recently closed deals in Boston, San Francisco, and Los Angeles.

The firm is open to all sectors and subsectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm is generally most interested in technology that address a large unmet need that may be in a crowded disease market but with an innovative strategy (i.e. hitting new targets). The firm is not particularly interested in orphan and rare diseases. The firm mostly invests in 510K devices due to its faster turnaround, but will also invest in devices in the PMA pathway depending on its stage. In therapeutics, the firm is interested in all subsectors including small molecule, biologics, cell therapy, and biosimilars. The firm invests in therapeutics that are past the pre-clinical stage at Phase I to on the market, as well as medical devices that are either at the clinical stage or on the market. The firm’s US branch is particularly more open to earlier stage investments, including innovative seed funding, while the China headquarters is more interested in clinical, late-stage technology. The firm is also interested in lab equipment and drug development enabling technologies, and is open to all indications.

The firm prefers a company with a strong management team with experience in the space. The firm will help the company fill spaces in the team if necessary, and will typically take a board seat after an investment. The US branch will mark technology with a China angle as priority for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Chinese Pharma Seeks Oncology, Neurology and Cardiovascular Therapeutic Investments Worldwide

A China-based pharmaceutical company is looking for any potential drug candidates that align with the company’s strategy. The firm is seeking to strengthen its R&D/manufacturing capability and portfolio/pipeline and is open to all kinds of collaboration models, including straight licensing, co-development, contract selling, equity investment, and M&A. The company is currently looking for assets globally with a focus on the US and Europe.

The firm is interested in mature or generic products in the following areas: Oncology, Neurology, Cardiovascular & Cerebrovascular, Rheumatology and Inflammation, Respiratory Diseases, Infectious Diseases (except HIV), and Pediatric Diseases (except rare disease). Early stage products or platform technology with high potential or clear differentiation will also be considered. In addition, the firm is exploring emerging areas in oncology, such as immunotherapy and cell therapy. In medical technology, the firm is interested in liquid biopsy, cancer diagnostics, and next generation sequencing, and would consider in-development and products.

The firm is looking for companies with capacity and experience in implementing R&D plans. The firm is interested in assets from the US and Europe, and intends to introduce the product to the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Redefining Early Stage Investments (RESI) Conference…Get On Board the Investor Train

By Dennis Ford, Founder & CEO, LSN

dennis-websit

When LSN founded the Redefining Early Stage Investments (RESI) conference in 2013, it was with the simple hope of creating an event that offered more to early stage life science investors and CEOs than the other partnering events that existed at the time. LSN’s business development team had visited partnering events and investor conferences throughout the USA and also internationally, and had met few active early stage investors at these events. As LSN began to cultivate relationships with these firms and discover what kinds of technologies they were seeking to invest in, we saw the opportunity to create an event that would bring these investors together to meet with fundraising CEOs whose technologies matched their investment mandates.

We’re now approaching the 8th RESI event, and over the last three years thousands of entrepreneurs and investors have come face to face at RESI to talk about new healthcare technologies. RESI has picked up the pace every year, becoming a quarterly event for the first time in 2016.

Not only that, but RESI has hit the road; following three successful RESI events in Boston, LSN saw the opportunity to host RESI in San Francisco during the annual healthcare conference week. Organizing an event so far from our home office in Boston was a tremendous challenge that took LSN beyond our previous comfort zone, but we found that RESI was well received as a part of the annual JPM ecosystem, filling a niche for early stage companies and investors that had previously been lacking in a conference week that’s primarily geared to later stage and publicly traded companies.

Last year, RESI also expanded to Houston as a part of Texas Medical Center’s efforts to build a “Third Coast” for healthcare innovation, supported by the resources, expertise and discoveries made at their member institutions. Houston has also attracted many other strategic partners to this effort, including Johnson & Johnson’s JLABS. Being in the right place at the right time is a gift in any innovative technology endeavor, and recognizing that RESI and JLABS are now coinciding in [geography], JLABS became RESI’s title sponsor.

This summer, RESI will take another step: the first international event, held at MaRS in Toronto on June 23rd. As we’ve added new events to the RESI circuit, we’ve brought new faces into LSN’s informal network at every new venue and uncovered the unique strengths and needs of each area.

So how have we continued to build RESI’s value? One question we typically ask fundraising CEOs is how many investor meetings they’ve had in the last year. We might typically hear they’ve pitched to a dozen or more investors in one year. RESI provides an opportunity to participate in both scheduled and ad hoc meetings, and many CEOs report up to 16 -20 meetings in one day, four times per year, with active investors who are a fit for their opportunity. With the potential for over 80 meetings for those that attend every event, there aren’t any other events that offer a comparable return on effort for a CEO on the road looking for development capital. And after 7 successful events, we’ve heard from many investors that they’ve conducted due diligence on companies that they’ve met at RESI.

LSN is looking ahead to a busy year for RESI, with events lined up in Houston (April 11th), Toronto (June 23rd) and Boston (September 13th) for our ever-expanding network to come together. We’re excited to be breaking new ground and hope you’ll join us on this global investor circuit.

RESI-Houston-2016_600

RESI Panel Announcement: Family Offices

By Lucy Parkinson, Director of Research, LSN

Family offices often catch the interest of entrepreneurs due to the possibility of committed, long-term capital from investors who look to the long view regarding their investment decisions.  Family offices may also have unique investment motivations that relate to the family’s particular expertise and history.  With a reputation for being deep-pocketed and flexible investors, life science CEOs are often interested in meeting with family office investors, and this panel will allow the RESI@TMCx audience to learn directly from family office investment staff about how they invest, what they look for in a life science opportunity, and how to find alignment with their needs.

Moderated by Colin Widen, CEO, Boston Innovation Capital, the panelists are:

If you’re interested in listening to this panel live at RESI, you can register for RESI@TMCx now.

RESI-Houston-2016_600

RESI Panel Announcement: Healthcare System Partners

By Shaoyu Chang, MD, MPH, Senior Research Manager, LSN

Shaoyu 10*10

The RESI team is pleased to debut a new panel on Healthcare System Partners at RESI@TMCx on April 11. In an article titled “Innovation as Discipline, Not Fad,” the New England Journal of Medicine called on healthcare organizations to embrace innovations and serve as the training ground to test their medical benefits, technical feasibility, and business viability. Many healthcare systems are doing just that. This panel will reveal the changing role healthcare organizations are playing in fostering innovation.

Moderated by Rebecca Kaul, Chief Innovation Officer, MD Anderson, this session will feature:

From innovation centers to investment vehicles, healthcare organizations have become critical partners for entrepreneurs. Whether you are considering generating user experience, conducting pilot studies, or receiving technical guidance, the value of face-to-face meetings with these institutions is unfathomable. At the heart of the world’s largest medical center, this panel will help entrepreneurs navigate complex healthcare systems and bring their companies to the next milestone.

Registering for the RESI Conference will give you the opportunity to listen to this panel live, connect with relevant investors and network with like-minded entrepreneurs.

RESI-Houston-2016_600

Hot Investor Mandate 1: Family Office Seeking Therapeutic Opportunities with a China Angle

An evergreen fund established by a family office in Asia is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in local-based businesses and co-invest in businesses overseas. The fund is currently focused on new opportunities in Greater China and Southeast Asia, while they are also interested in US, Canada, and EU-based companies with a China angle.

Currently, the firm is interested in cutting edge, innovative therapeutic and platform technologies in cancer, CNS, and chronic diseases. The fund considers all stages from preclinical through pre-IPO. The fund also considers a broad range of technologies including medical devices, diagnostics, healthcare services, and nutraceuticals. In medical devices, the fund is open to all indications and prefers later stage projects with proof of concept.

The firm is looking for competent, experienced, and reliable management teams when considering investment. Prior to deciding on allocations, the fund’s management team typically spends months interacting with candidate companies to determine their track record, quality of scientific research, technical expertise, and flexibility and reliability in working with investors. The fund prefers to work with Greater China-based companies or foreign businesses that are seeking to enter the Greater China market. The fund typically requires a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com